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SCIENTIFIC OPINION  
Scientific Opinion on Rooster Combs Extract
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2, 3 
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to carry out the additional assessment for „Rooster Combs Extract‟ (RCE) as a food 
ingredient in the context of Regulation (EC) No 258/97, taking into account the comments and objections of a 
scientific nature raised by Member States. Rooster combs extract results from a production process involving 
enzymatic hydrolysis of rooster combs and subsequent filtration, concentration and precipitation steps. The 
principle constituents of RCE are the glycosaminoglycans hyaluronic acid, chondroitin sulphate A and dermatan 
sulphate. The applicant intends to add RCE to a number of dairy products with a recommended maximum intake 
of 80 mg RCE per portion and per day. The target population is the general population, with the exception of 
pregnant women, children and people with adverse reactions to sodium hyaluronate and/or avian protein. In the 
high intake scenario for “consumers only”, the highest daily intake would occur in adults in Belgium (0.788 g). 
The highest intake scenario for “all subjects” was estimated for adolescents in Denmark (0.427 g/day). The Panel 
notes that no adverse effects were observed at the highest tested dose of 600 mg/kg bw per day in a 90-day oral 
toxicity study in rats. Considering the nature, the natural occurrence and previous consumption of RCE 
constituents, the Panel is of the opinion that the margin between the intended as well as the estimated maximum 
possible intake of RCE in relation to the highest dose administered to rats without adverse effects in a subchronic 
oral toxicity study is sufficient. The Panel concludes that the novel food ingredient, Rooster Comb Extract, is 
safe under the proposed uses and use levels. 
© European Food Safety Authority, 2013 
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SUMMARY 
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition 
and Allergies (NDA) was asked to carry out the additional assessment for „Rooster Combs Extract‟ 
(RCE) as a food ingredient in the context of Regulation (EC) No 258/97, taking into account the 
comments and objections of a scientific nature raised by Member States. 
Rooster combs extract results from a production process involving enzymatic hydrolysis of rooster 
combs and subsequent filtration, concentration and precipitation steps. The principle constituents of 
RCE are the glycosaminoglycans hyaluronic acid, chondroitin sulphate A and dermatan sulphate 
(chondroitin sulphate B). The Panel considers that the information provided on the manufacturing 
process as well as on the composition and specification of the novel food ingredient RCE is sufficient 
and does not raise safety concerns.  
Rooster combs have a history of consumption in the European Union. Glycosaminoglycans, the main 
constituents of RCE, occur endogenously in mammalian organisms and are thus consumed as part of 
the normal diet.  
The applicant intends to add RCE to liquid milk, milk-based products (milk-based fermented 
beverages), yoghurts and fromage frais with a recommended maximum intake of 80 mg RCE per 
portion and per day. The target population is the general population, with the exception of pregnant 
women, children, and people with adverse reactions to sodium hyaluronate and/or avian protein. 
Based on these proposed uses and use levels, the applicant conducted an intake estimation based on 
the Comprehensive European Food Consumption Database. Intake data were specified by country, 
food category, age group, for “all subjects” and for “consumers only”. The mean daily intake 
estimates for “consumers only” and for “all subjects” were calculated to be highest for the 
Netherlands (0.455 g in the adult population) and for Denmark (0.255 g in adolescents), respectively. 
According to the model applied by the applicant for the high intake scenario for “consumers only”, 
the highest daily intake would occur in adults in Belgium (0.788 g). The highest intake scenario for 
“all subjects” was estimated for adolescents in Denmark (0.427 g/day). The Panel notes that this type 
of intake methodology for fortified foods is generally considered to be “high intake”, as a result of 
conservative assumptions made in the intake estimates where it is assumed that all food products 
within a food category contain the ingredient at the maximum specified level of use.  
Rooster combs extract did not show mutagenic activity in tests for gene mutations in bacteria up to 
the highest tested dose of 5000 µg/plate in the presence and absence of metabolic activation. 
Considering the nature of the test material and the negative results in tests for gene mutations in 
bacteria, the Panel had no safety concerns related to genotoxicity. The Panel notes that no adverse 
effects were observed at the highest tested dose of 600 mg/kg bw per day in a 90-day subchronic oral 
toxicity study in rats.  
The applicant provided two articles on two randomised placebo-controlled human studies. They 
included some endpoints on safety and tolerability but were primarily designed to study possible 
beneficial effects of RCE produced by the applicant. The Panel notes the low number of subjects, the 
relatively low dose, the number of safety endpoints studied, and the limited information regarding 
these safety endpoints (e.g. the parameters of the biochemical profile were not specified). The Panel 
considers that no conclusion can be drawn from the human studies on the safety of RCE. Panel 
considers that the risk of allergic reactions cannot be ruled out, but is not dissimilar to other products 
derived from chicken meat. The applicant‟s intended daily dose of 80 mg RCE corresponds to a 
production yield of one rooster comb, which corresponds to about 1 mg RCE per kg bw for an adult. 
A mean and high intake estimate of about 450 mg/day and 790 mg/day, respectively, for adults are 
derived from an intake assessment based on conservative assumptions. Considering the nature, the 
natural occurrence and previous consumption of RCE constituents, the Panel is of the opinion that the 
margin between the intended as well as the estimated maximum possible intake of RCE in relation to 
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the highest dose administered to rats without adverse effects in a subchronic oral toxicity study is 
sufficient.  
The Panel concludes that the novel food ingredient, Rooster Comb Extract, is safe under the proposed 
uses and use levels. 
 
 
 
Safety of „Rooster Combs Extract‟ 
 
 
4 EFSA Journal 2013;11(6):3260 
TABLE OF CONTENTS 
Abstract .................................................................................................................................................... 1 
Key words ................................................................................................................................................ 1 
Summary .................................................................................................................................................. 2 
Table of contents ...................................................................................................................................... 4 
Background as provided by the European Commission .......................................................................... 5 
Terms of reference as provided by the European Commission ............................................................... 6 
Assessment ............................................................................................................................................... 7 
1. Specification of the Novel Food (NF) ............................................................................................. 7 
2. Effect of the production process applied to the NF ....................................................................... 10 
3. History of the organism used as a source ...................................................................................... 11 
4. Anticipated intake/extent of the use of the NF .............................................................................. 11 
5. Information from previous exposure to the NF or its source ........................................................ 12 
6. Nutritional information on the NF ................................................................................................. 12 
7. Microbiological information on the NF ........................................................................................ 12 
8. Toxicological information on the NF ............................................................................................ 12 
8.1. Absorption, distribution, metabolism and elimination (ADME) .......................................... 12 
8.2. Toxicological studies ............................................................................................................ 13 
8.2.1. Genotoxicity ..................................................................................................................... 13 
8.2.2. Acute toxicity ................................................................................................................... 13 
8.2.3. Subacute toxicity .............................................................................................................. 13 
8.2.4. Subchronic toxicity ........................................................................................................... 14 
8.3. Allergenicity ......................................................................................................................... 14 
8.4. Human studies ....................................................................................................................... 14 
Discussion .............................................................................................................................................. 15 
Conclusions ............................................................................................................................................ 15 
Documentation provided to EFSA ......................................................................................................... 15 
References .............................................................................................................................................. 16 
Abbreviations ......................................................................................................................................... 18 
Appendix ................................................................................................................................................ 19 
Safety of „Rooster Combs Extract‟ 
 
 
5 EFSA Journal 2013;11(6):3260 
BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
On 8 February 2011, Bioiberica S.A. (Spain) submitted a request under Article 4 of the Novel Food 
Regulation (EC) N° 258/97 to place on the market „Rooster Combs Extract‟ (RCE) as a novel food 
ingredient. 
On 25 October 2011, the competent authorities of the United Kingdom forwarded to the Commission 
their initial assessment report, which came to the conclusion that RCE may be placed on the market. 
On 10 November 2011, the Commission forwarded the initial assessment report to the other Member 
States. Several of the Member States submitted comments or raised objections. 
The concerns of a scientific nature raised by the Member States can be summarized as follows: 
 The mass balance according to the proposed specification indicates that some 20 % of the 
product has not been specified. The application itself indicates that, in addition to the 60-80 % 
sodium hyaluronate, the product contains glycosaminoglycans such as chondroitin sulphate 
and dermatan sulphate (about 20 %) and also partially hydrolysed proteins (about 20 %). The 
glycosaminoglycans were not, however, further determined either in the specification or in 
analyses of the product concerned. 
 The cited nitrogen content (44 g/100 g) in the section “nutritional information” is many times 
higher than that specified in Tables 1-3 (not more than 8 % and mean of 6.43 %, 
respectively). 
 The data on the nitrogen content are ambiguous, because the applicant‟s analyses do not 
distinguish between nitrogen molecules originating from protein and the N-acetyl-
glucosamine component of hyaluronate (and other glycosaminoglycans). Hence, no reliable 
figures are available concerning the extract‟s maximum protein concentration either. Proteins 
are not specified separately, although the nitrogen content (≤ 8 %) is.  
 The nitrogen mass balance according to total Kjeldahl nitrogen and the Lowry protein assay is 
inconclusive in itself: the mole percent of nitrogen in sodium hyaluronate is some 3.5 %, 
which, with an average content of 65.5 % sodium hyaluronate, would mean a nitrogen content 
of some 2.3 %. If we add the 0.8 % protein nitrogen (ca. 16 % of the protein content of 
5.1 %), the total nitrogen content is 3.1 %. On average, however, a total nitrogen content of 
6.5 % was found. Even an additional examination of the nitrogen content in the 
glycosaminoglycans does not adequately clarify the nitrogen distribution in the product. 
 The specification of the product concerned differs significantly from that of the European 
Pharmacopoeia for sodium hyaluronate, which, for example, indicates a maximum sulphated 
glycosaminoglycan content of 1 % and a maximum protein content of 0.3-0.1 %.  
 No tests confirming the identity of the main constituents and other extraneous substances 
have been conducted or presented.  
 It is not clear how the fibre content (36 g/100 g) has been determined. 
 The application does not identify the test facility that analysed the product. It should be noted 
that only test laboratories accredited for the tests in question should be used for analyses. 
Also no test reports are available. 
 The information provided regarding the production process was considered to be 
insufficiently detailed to assess the applicant‟s assertion that the substances making up the 
extract are roughly 1 % of those making up the rooster combs used as source material.  
Safety of „Rooster Combs Extract‟ 
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 It is necessary to better specify the methods for adding the NF to the milk products they are 
intended for. The impact of the production process for these products such as, for example, 
the stability of the NF under heat treatments ought to be studied. 
 The applicant claims that during the production process the product undergoes a heat 
treatment which inactivates the production enzyme. However, the relevant process conditions 
are not specified and the summary data do not adequately demonstrate the effectiveness of the 
inactivation procedure. Moreover, it is not apparent from the available information whether 
the inactivated enzyme is removed. Consequently, it is not possible to tell what proportion of 
the total protein content is accounted for by the enzyme. A Member State also asked for 
assurance that the enzyme used is of food-grade. 
 Previous consumption data would be useful. 
 Without a clear specification of the use levels in the relevant products referred to by the 
applicant, it is not possible to reliably estimate intake of the novel product. 
 The petitioner must justify the limits that it has proposed for contaminants. 
 The absence of data on the metabolism of the NF was regretted. 
 The applicant claims to have used the product which is the subject of the application in the 
analyses. The documentation does not indicate, however, whether the test substances "Hyal-
Joint" and "IB 0004“ meet the specification of the product concerned or differ from it. 
 The applicant has submitted only a draft report on the 90-day study with rats. On the basis of 
the pathology information provided, the study appears to have been comprehensive, but it is 
not clear why OECD guideline 452 for chronic research has been used in this context. In view 
of the paucity of safety data, a signed finalised version of this essential study report is a 
prerequisite for making a definitive assessment. 
 The allergenicity should be addressed. In the context of possible allergenicity, the size 
distribution of the protein hydrolysis fragments is important as well. 
 The additional data provided by the applicant does not conclusively demonstrate the absence 
of serological cross-reactivity between anti-chicken egg protein IgE and proteins in the 
extract, because the size and characteristics of the serum pool of patients with egg protein 
allergy was not clearly stated. 
 The safety of the NF in young people has not been adequately studied.  
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
In accordance with Article 29 (1) (a) of Regulation (EC) No 178/2002, the European Food Safety 
Authority is asked to carry out the additional assessment of „Rooster Combs Extract‟ as a food 
ingredient in the context of Regulation (EC) No 258/97. 
EFSA is asked to carry out the additional assessment and to consider the elements of scientific nature 
in the comments raised by the other Member States. 
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7 EFSA Journal 2013;11(6):3260 
ASSESSMENT 
In accordance with Commission Recommendation 97/618/EC, „Rooster Combs Extract (RCE)‟ is 
allocated to Class 2.1 „a complex (non-GM derived) novel food ingredient, the source of the novel 
food having a history of food use in the community‟. The assessment of the safety of this novel food 
ingredient is based on data supplied in the original application, the initial assessment by the 
competent authority of the United Kingdom, the comments and objections of the other Member 
States, and the responses of the applicant to these questions and those of the United Kingdom. The 
data are required to comply with the information required for novel foods of Class 2.1, i.e. structured 
schemes I, II, III, IX, X, XI, XII and XIII. It is noted that the novel food ingredient (NFI) is intended 
by the applicant to be added to certain dairy products (i.e. milk-based fermented beverages, yoghurts, 
milks and fromage frais) to support joint health of the general population. This assessment concerns 
only risk that might be associated with consumption, and is not an assessment of the efficacy of 
„RCE‟ with regard to any claimed benefit. 
1. Specification of the Novel Food (NF)  
Rooster combs extract (RCE) results from a production process involving enzymatic hydrolysis of 
rooster combs and subsequent filtration, concentration and precipitation steps. The principle 
constituents of RCE are the glycosaminoglycans hyaluronic acid, chondroitin sulphate A and 
dermatan sulphate (chondroitin sulphate B). Their structures are depicted in Figure 1. 
 
CH2OH
n
1
CH2OH
n
2
n
CH2OH
3
 
 
Figure 1: Structures of hyaluronic acid (1), chondroitin sulphate A (2), and dermatan sulphate 
(chondroitin sulphate B) (3) 
 
Hyaluronic acid (1) is a non-sulphated glycosaminoglycan. Its basic unit is a disaccharide of D-
glucuronic acid and N-acetyl-D-glucosamine linked by a ß-1,3-glycosidic bond; these disaccharides 
are polymerized via ß-1,4-glycosidic bonds. 
Chondroitin sulphate A (2) is a C4-sulphated glycosaminoglycan. Its basic units are disaccharides of 
D-glucuronic acid and N-acetyl-D-galactosamine linked by a ß-1,3-glycosidic bond; these are 
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polymerized via ß-1,4-glycosidic bonds. In the disaccharide unit of dermatan sulphate (chondroitin 
sulphate B) (3) glucuronic acid is replaced by the epimeric iduronic acid.  
The applicant provided compositional data on ten batches of RCE produced in 2008 and 2009 (Table 
1). 
Table 1:  Compositional data of RCE batches produced in 2008 and 2009 
Parameter 
8/0001 
Feb 08 
8/0010 
Apr 08 
8/0021 
Jul 08 
8/0038 
Nov 08 
9/0001 
Jan 09 
9/0008 
Feb 09 
9/0009 
Mar 09 
9/0010 
Mar 09 
9/0011 
Apr 09 
9/0012 
Apr 09 
Glucuronic acid,  
expressed as  
sodium hyaluronate  
(%) 
 
65 
 
61 
 
65 
 
68 
 
67.5 
 
69 
 
65 
 
64 
 
62 
 
67 
pH 7.2 7.4 6.7 6.3 6.0 6.6 6.2 6.4 6.5 6.7 
Chlorides (%) 0.5 0.7 0.4 0.4 0.4 0.5 0.6 0.8 0.5 0.5 
Nitrogen (Kjeldahl)   
(%) 
6.0 5.0 7.0 7.0 7.0 7.0 7.0 6.0 6.0 6.0 
Loss on drying  
(%) 
8.3 7.7 5.5 5.0 5.4 6.0 5.0 6.5 6.0 6.0 
Heavy metals  
(mg/kg) 
≤ 10 ≤ 10 ≤ 10 ≤ 10 ≤ 10 ≤ 10 ≤ 10 ≤ 10 ≤ 10 ≤ 10 
Mercury (mg/kg) < 0.10 - - < 0.10 - - - - - < 0.10 
Arsenic (mg/kg) < 1 - - < 1 - - - - - < 1 
Cadmium (mg/kg) < 1 - - < 1 - - - - - < 1 
Chromium (mg/kg) < 10 - - < 10 - - - - - < 10 
Lead (mg/kg) ≤ 0.5 ≤ 0.5 ≤ 0.5 ≤ 0.5 ≤ 0.5 ≤ 0.5 ≤ 0.5 ≤ 0.5 ≤ 0.5 ≤ 0.5 
Dioxins/Furans  
(pg/g) 
0.024 - - 0.04 - - - - - 0.07 
PCBs (pg/g) 0.004 - - 0.006 - - - - - 0.01 
Total aerobic  
count  (cfu/g) 
≤ 102 ≤ 102 ≤ 102 ≤ 102 ≤ 102 ≤ 102 ≤ 102 ≤ 102 ≤ 102 ≤ 102 
E. coli per g n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
Salmonella per g n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
S. aureus per g n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
P. aeruginosa per g n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
 „n.d.‟ = not detected; „-‟ = not tested 
 
In addition, data were reported on the contents of glucuronic acid, expressed as sodium hyaluronate 
for a total of 45 batches of RCE produced in 2008 (mean: 64.6 %; median: 65.0 %; standard 
deviation: 2.57; standard error: 0.41). 
Upon request by the Panel, the applicant provided more refined compositional data, based in 
particular on specific analyses of hyaluronic acid, chondroitin sulphate and dermatan sulphate, using 
methods based on capillary electrophoresis and HPLC. In addition, revised data for the contents of 
fibre, free amino acids and protein were provided. The data given for four batches of RCE 
manufactured between September 2011 and November 2012, and for the batch (FTAH04-08, “Hyal 
Joint”) used for the subchronic study and the genotoxicity tests, are shown in Table 2. 
Safety of „Rooster Combs Extract‟ 
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Table 2:  Compositional data of industrially produced batches of RCE 
Parameters 
( %) 
Batches  
12/0001 12/0015 12/0027 12/0040 FTAH04-08* Method 
Hyaluronic acid 61.7 63.5 65.6 69.1 62.1 
HPLC (Coleman et al., 1997) 
and capillary electrophoresis 
(Malavaki et al., 2008) 
Chondroitin sulphate A  2.13 2.21 2.23 2.43 0.45 
Capillary electrophoresis 
(Malavaki et al., 2008) 
Chondroitin sulphate B  11.27 12.23 17.12 8.85 11.48 
Capillary electrophoresis 
(Malavaki et al., 2008) 
Fibre  0.4 < 0.1 < 0.1 < 0.1 < 0.2 Weende 
Free amino acids 1.7 1.3 1.4 1.4 0.3 HPLC 
Protein  21.4 18.5 15.5 18.1 12.6 Lowry 
Loss on drying 6 7 6 8 8 Eur. Ph. 2.2.32 
*  used for genotoxicity and subchronic toxicity testing 
 
In response to the objections by Member States and the request by the Panel, the applicant also 
provided data on the protein contents determined in several batches of RCE using the Lowry method. 
The protein contents in batches of RCE determined by the Lowry method ranged between 13.0 (batch 
No.08/0021) and 21.4 % (batch No. 12/0015).  
The applicant proposed the specifications shown in Table 3. 
Table 3:  Specifications for RCE as proposed by the applicant 
Parameter Limits Method 
Glucuronic acid, expressed as sodium 
hyaluronate ( %) 
60 - 80 Eur. Ph. Monograph 1472 
Hyaluronic acid ( %) 60 - 80 
HPLC (Coleman et al., 1997) 
and  capillary electrophoresis 
(Malavaki et al., 2008) 
Chondroitin sulphate A ( %) ≤ 5 
Capillary electrophoresis 
(Malavaki et al., 2008) 
Dermatan sulphate 
(Chondroitin sulphate B) ( %) 
≤ 25 
Capillary electrophoresis 
(Malavaki et al., 2008) 
   
Appearance 
White or almost white 
hygroscopic powder 
visual 
pH 5.0 - 8.5 Eur. Ph. 2.2.3 
Chlorides ( %) ≤ 1 Mohr 
Nitrogen (Kjeldahl) ( %) ≤ 8 Eur. Ph. 2.5.9 
Protein (Lowry) ( %) ≤ 25 Eur. Ph. 2.5.33 
Loss on drying ( %) ≤ 10 Eur. Ph. 2.2.32 
Heavy metals (mg/kg) ≤ 10 USP 231 
Mercury (mg/kg) ≤ 0.1 Eur. Ph. 2.2.58 
Arsenic (mg/kg) ≤ 1 Eur. Ph. 2.2.58 
Safety of „Rooster Combs Extract‟ 
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Parameter Limits Method 
Cadmium (mg/kg) ≤ 1 Eur. Ph. 2.2.58 
Chromium (mg/kg) ≤ 10 Eur. Ph. 2.2.58 
Lead (mg/kg) ≤ 0.5 Eur. Ph. 2.2.58 
Dioxins and furans (pg/g) ≤ 2.0 EPA Method 1613 
PCBs (pg/g) ≤ 4.0 EPA Method 613 
Microbiological parameters   
Total viable aerobic count ≤  102 cfu/g Eur. Ph. 2.6.12 
Escherichia coli absence/1g Eur. Ph. 2.6.13 
Salmonella sp. absence/g Eur. Ph. 2.6.13 
Staphylococcus aureus absence/g Eur. Ph. 2.6.13 
Pseudomonas aeruginosa absence/g Eur. Ph. 2.6.13 
 
The Panel considers that the information provided on the composition, specification and data from 
batch testing are sufficient and do not raise safety concerns.  
2. Effect of the production process applied to the NF  
The production process of RCE includes an enzymatic hydrolysis, followed by filtration, 
concentration and precipitation steps. 
A flowchart of the production process including a mass balance for each manufacturing step has been 
provided; starting from an initial loading of 5 000 kg of rooster combs, 50 kg of RCE is obtained as 
final product. 
According to the applicant, rooster combs are sourced from poultry declared fit for human 
consumption in authorised slaughterhouses. 
An alcalase is used for the enzymatic hydrolysis. The commercially available enzyme preparation 
employed is produced from a non-genetically modified strain of Bacillus licheniformis. The supplier 
provided a statement on the current approval status referring to the acceptance by the Danish Food 
Authority for it to be used for production of protein hydrolysates, and to the inclusion in the French 
positive list regarding the use of processing aids in the manufacturing of human food.  
After the hydrolysis step, the enzyme is inactivated by heat-treatment. The inactivation was 
demonstrated by determining enzyme concentrations and activities in three batches before and after 
the heat-treatment. Before the thermal treatment, the enzyme protein concentration determined via 
ELISA ranged from 7.63 x 10
5
 to 8.24 x 10
5 
ng/g. After the inactivation step, the concentration was 
below the limit of detection of the employed assay (102 ng/g). The enzyme activity (4.35-4.70 x 10
-2
 
AU/g before the heat treatment) was also below the limit of detection of the employed assay (5.8 x 10
-
6
 AU/g) after the heat-treatment.   
According to a certificate of the supplier, the salt (NaCl) used in the precipitation step is of food 
grade. The NaCl concentration is adjusted. The concentration of chlorides in the final product is less 
than 1 %. 
The applicant states that its quality management system is based on ISO 9001 standards, which 
include a hazard analysis and critical control points system (HACCP).  
Studies under accelerated storage conditions (40 ± 2º C / 75 ± 5 % Relative Humidity, RH, for 6 
months) and long-term storage conditions (25 ± 2º C / 60 ± 5 % RH, 40-43 months) have been 
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conducted with three different production batches of RCE. The Panel considers that storage under the 
employed conditions, using as a primary packaging a triple low density polyethylene bag, and a metal 
drum as a secondary packaging, does not affect the stability of the RCE.  
The stability of six different concentrations (from 0.16-1.28 mg RCE/g) in yoghurts was assessed 
under refrigerated storage conditions for 1 and 1.5 months, which covers the mean shelf life of a 
standard commercial yoghurt (normally three weeks). Analyses show that RCE remained stable with 
only minor variations in RCE concentration, which are considered not relevant for the safety of the 
products.  
The production process encompasses steps commonly used in food technology. The Panel considers 
that the production process is sufficiently described by the applicant and does not raise safety 
concerns. 
3. History of the organism used as a source  
Rooster Combs Extract is obtained from rooster combs from Gallus gallus. Rooster comb is a 
moderately thin, fleshy formation of smooth soft surface texture, firmly attached from the beak along 
the top of the skull with a strong base. Rooster comb can measure more than 7 cm in length and weigh 
more than 8 grams. Rooster combs have a history of human consumption in Europe and continue to be 
part of the normal diet in some countries, including frequently consumed dishes such as home-made 
recipes (stews) and industrially prepared soup concentrates.  
4. Anticipated intake/extent of the use of the NF 
The applicant intends to add RCE to liquid milk, milk-based products (milk based fermented 
beverages), yoghurts and fromage frais with a recommended maximum intake of 80 mg RCE per 
portion and per day. The target population is the general population, with the exception of pregnant 
women, children and people with adverse reactions to sodium hyaluronate and/or avian protein. 
The maximum concentrations intended for each of the food categories are given in Table 4. 
Table 4:  Intended maximum concentrations of RCE 
Dairy product 
Maximum use level 
(mg/portion) 
Portion size 
a
 (g) 
Maximum level 
(mg/100g food) 
Liquid milk 80 200 40 
Milk-based product (milk 
based fermented 
beverages) 
80 100 80 
Yoghurt 80 125 64 
Fromage frais 80 75
 b
 106.7 
a Portion sizes according to those established by the UK Food Standards Agency  
(http://www.food.gov.uk/multimedia/pdfs/ann3portions.pdf)  
b Average size of retail products in Spain 2012 
 
The applicant indicated the use of the Comprehensive European Food Consumption Database (EFSA, 
2011) for the intake estimates. These data were specified by country, food category, age group, for 
“all subjects” and for “consumers only”. The mean intake estimate was calculated by adding the sum 
of the mean intake from all four food categories (Table 5, Appendix). The estimated high intake 
scenario of the applicant was based on the sum of the mean intake values of three food matrices (milk, 
yoghurt and fromage frais) plus the highest 95
th
 percentile intake estimated for the four food 
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categories, which was estimated for milk-based products. Since “Fromage frais” is not a category in 
the Comprehensive European Food Consumption Database, the applicant used total cheese 
consumption as the starting point. Based on Spain and UK survey data, the percentage of fresh cheese 
consumption from total cheese intake has been calculated for Spain (27 %) and the UK (14 %). The 
figure for Spain (27 %) was then used as a proxy of fresh cheese intake for other European countries. 
The mean daily intake estimates for “consumers only” and for “all subjects” were calculated to be 
highest for the Netherlands (0.455 g in the adult population) and for Denmark (0.255 g in 
adolescents), respectively (Table 5, Appendix).  
According to the model applied by the applicant for the high intake scenario for “consumers only”, 
the highest daily intake would occur in adults in Belgium (0.788 g). The highest intake scenario for 
“all subjects” was estimated for adolescents in Denmark (0.427 g/day) (Table 6, Appendix).  
The Panel notes that this type of intake methodology for fortified foods is generally considered to be 
“high intake”, as a result of conservative assumptions made in the consumption estimates where it is 
assumed that all food products within a food category contain the ingredient at the maximum 
specified level of use.  
5. Information from previous exposure to the NF or its source 
The applicant notes that rooster combs have been consumed in the EU. Also, there are several food 
supplements on the EU market (Belgium, France, Germany, Ireland, Italy, Portugal, Spain and UK), 
containing sodium hyaluronate. According to the applicant, these supplements do not specify the 
source of sodium hyaluronate except one which is obtained by microbial fermentation.  
Rooster Combs Extract‟s compounds are present in a comb at an approximate proportion of 1 %. The 
applicant‟s intended daily dose of 80 mg represents the production yield from a single rooster comb. 
Glycosaminoglycans, the main constituents of RCE, occur endogenously in mammalian organisms 
and are thus consumed as part of the normal diet. 
6. Nutritional information on the NF 
The applicant states that RCE in dairy products is not intended to replace any existing food 
ingredient. Based on the information provided on the nature, composition and proposed use levels, the 
Panel considers that the intake of RCE is not nutritionally disadvantageous.   
7. Microbiological information on the NF 
The applicant has provided microbiological specifications and has also supplied results of analyses 
for ten independent lots of RCE. All batches comply with the specifications.   
The Panel has no safety concerns with regard to the microbiological specifications of the novel food 
ingredient. 
8. Toxicological information on the NF 
8.1. Absorption, distribution, metabolism and elimination (ADME) 
On request of the Panel to provide information on the absorption, distribution, metabolism and 
excretion (ADME) of hyaluronic acid (HA), which is the main constituent of RCE, the applicant 
provided the results of a study using the ex vivo everted gut sac model. The Panel notes that the 
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applicant did not provide data on hyaluronic acid, but determined the amount of glycosaminoglycans 
passing through the intestinal wall by applying a spectrophotometric method, which detects sulphated 
glycosaminoglycans (Farndale et al., 1982). The authors concluded that absorption of RCE through 
the duodenum, jejunum and ileum was 38 %, 22 % and 8 %, respectively (Torrent et al., 2010).  
The applicant also provided information on the metabolic fate of HA obtained from the scientific 
literature. After oral administration of a single dose of commercial food grade sodium hyaluronate 
preparations (labelled with 
99m
Tc) to rats, total excretion of the ingested dose over 72 h was 84.6-
92.3 % in faeces and 2.0-3.2 % in urine. Radioactivity was detected at different time points in blood 
and all organs examined, except for the brain, with organs of the gastrointestinal tract containing the 
vast majority. Based on the total results of this study, which also included data from dogs, the authors 
estimated that the percentage of HA entering the systemic circulation after oral administration is 
similar to that reported for other glycosaminoglycans, i.e. 5-20 % (Balogh et al., 2008). This 
conclusion is not in line with that of other investigators, who compared the distribution profiles and 
elimination pathways of 
99m
Tc-labelled and 
14
C-labelled HA, and found only negligible radioactivity 
absorption from the gastrointestinal tract after oral administration (Laznicek et al., 2012). 
The Panel notes that the information provided on ADME is limited and inconsistent and does not 
allow conclusions to be drawn. 
8.2. Toxicological studies  
The applicant has conducted a range of toxicological studies, which are described below. The relevant 
results from these studies are summarised in the publication of Canut et al. (2012). On request from 
EFSA, the applicant provided compositional data showing that the test material used in the studies on 
subchronic toxicity and genotoxicity (designated „Hyal-Joint‟) complied with the proposed 
specification for RCE (see section 1, Table 3). 
8.2.1. Genotoxicity 
Tests for gene mutations in bacteria were performed according to OECD Guideline 471, and in 
compliance with GLP principles (Bioiberica, 2008). Using Salmonella typhimurium strains TA 1 535, 
TA 1 537, TA 98 and TA 100, and the Escherichia coli strain WP2 uvrA pkM101, RCE did not show 
mutagenic activity up to the highest tested dose of 5000 µg/plate in the presence and absence of 
metabolic activation (S9 mix). Considering the nature of the test material and the negative results in 
tests for gene mutations in bacteria, the Panel had no safety concerns related to genotoxicity. 
8.2.2. Acute toxicity 
In an acute oral toxicity study (GLP complying) RCE was administered via stomach tube to Sprague 
Dawley rats (Bioiberica, 2004). There were no indications of adverse effects up to the highest tested 
dose of 2 000 mg/kg body weight (bw).  
8.2.3. Subacute toxicity 
A two-week dose range finding study (GLP complying) was performed in Wistar rats (Bioiberica, 
2005). Rooster Comb Extract was administered by gavage to groups of 5 male and 5 female animals 
(strain HsdBrlHan:WIST) at doses of 200, 400 or 600 mg/kg bw per day for two weeks. The control 
group just received the vehicle (distilled water). Based on the results of this study a dose of 
600 mg/kg bw per day was considered as an appropriate high dose in a 4-week study.  
In a 4-week study (subacute toxicity study), groups of 10 male and 10 female rats of the same strain 
received RCE at doses of 0, 5, 55 or 600 mg/kg bw per day via stomach tube. According to the study 
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report, no adverse effects were observed at the highest dose tested. The Panel notes that the study 
report (available only in Spanish) was not signed, did not contain a GLP certificate, and did not make 
reference to OECD Guideline 407.  
8.2.4. Subchronic toxicity 
Rooster Comb Extract was also tested in a subchronic oral toxicity study, which was performed 
according to Commission Directive 96/54/EEC and in compliance with GLP principles (Bioiberica, 
2009). Groups of 10 male and 10 female Wistar rats (strain HanBrl:Wist) were administered doses of 
5, 55 or 600 mg/kg bw per day via stomach tube for 13 weeks. The control group received the vehicle 
alone. Two additional groups of 5 male and 5 female animals were administered the high dose or 
vehicle for 13 weeks and received a standard rodent diet for 4 weeks thereafter (recovery period).  
One female animal of the control group died on day 5 of the treatment period because of incorrect 
gavage. Regular observations of the remaining animals revealed no clinically relevant findings. 
Salivation was recorded occasionally after administration in some animals of the three treatment 
groups. Body weight development and food consumption were comparable in all groups. 
Haematology analysis showed isolated statistically significant differences in relation to the control 
group, which are regarded as incidental findings (i.e. higher mean cellular haemoglobin (MCH) in 
males of the low dose group; higher mean cellular volume (MCV) and lower mean reticulocyte counts 
in males of the intermediate dose group). Females of the high dose group showed significantly higher 
mean platelet counts at the end of the treatment period, but no difference was noted at the end of the 
4-week recovery period. Taking into account the absence of changes in related parameters as well as 
the historical control data provided by the applicant upon request, the Panel does not consider the 
observed difference as a treatment-related effect. No significant differences were noted in clinical-
chemistry and urine analyses.  
Determination of the weights of selected organs and tissues at necropsy after 13 weeks showed 
significantly higher liver weights in females of the low dose group (absolute and in relation to brain 
weight) and the high dose group (absolute and in relation to body weight and brain weight). These 
changes were not dose-related, and at the end of the recovery period female liver weights in the high 
dose group were significantly lower compared with the controls. Histopathological examinations of 
the liver as well as other selected organs and tissues did not reveal relevant differences in the types 
and incidences of findings between the high dose and the control group. The Panel notes that no 
adverse effects were observed at the highest dose tested of 600 mg/kg bw per day. 
8.3. Allergenicity 
The applicant proposes labelling to inform people who are allergic to avian proteins. The Panel 
considers that the risk of allergic reactions cannot be ruled out, but is not dissimilar to other products 
derived from chicken meat. 
8.4. Human studies 
The applicant provided two articles on two randomised placebo-controlled human studies. They 
included some endpoints on safety and tolerability but were primarily designed to study possible 
beneficial effects of RCE produced by the applicant. In the study by Kalman et al. (2008), 20 adults 
with osteoarthritis of knee(s) but otherwise of good general health received one capsule per day with 
80 mg of RCE or placebo after breakfast over 8 weeks. Tolerability and safety parameters were the 
incidence and severity of adverse events reported throughout the study as well as changes in blood 
pressure and heart rate. Laboratory tests included blood cell count and biochemical profile. Treatment 
compliance was also recorded. Non-compliance was defined as taking less than 80 % of the 
prescribed course of the study product. No serious adverse events were reported. Two adverse events 
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were recorded for the placebo group, one subject of the RCE group complained of acute knee pain. 
No significant changes were observed in vital signs, body weight or laboratory tests between the test 
and the control group. The Panel notes that the article does not specify which biochemical endpoints 
were tested. The Panel considers that the low number of subjects, the relatively low dose, the number 
of safety endpoints studied, and the limited information on these safety endpoints (e.g. the parameters 
of the biochemical profile were not specified) do not allow conclusions to be drawn on the safety of 
RCE. The other RCT enrolled 40 adults who were given one 80 mg RCE-supplemented or non-
supplemented yoghurt per day for 12 weeks (Martinez-Puig et al., 2012). While the article indicated 
that only blood pressure, heart rate and body weight changes were studied safety endpoints, the 
applicant also claims that “subjective and physical adverse events” were endpoints. No significant 
differences were reported between the two groups. The Panel notes that the relatively low dose, the 
number of safety endpoints studied, and the limited information on these safety endpoints do not 
allow conclusions to be drawn on the safety of RCE. The Panel considers that no conclusion can be 
drawn from the human studies on the safety of RCE. 
DISCUSSION 
The Panel considers that the information provided on the manufacturing process as well as on the 
composition and specification of the novel food ingredient RCE is sufficient and does not raise safety 
concerns.  
Rooster combs have a history of consumption in the European Union. Glycosaminoglycans, the main 
constituents of RCE, occur endogenously in mammalian organisms and are thus consumed as part of 
the normal diet. 
The applicant‟s intended daily dose of 80 mg RCE corresponds to a production yield of one rooster 
comb which corresponds to about 1 mg RCE per kg bw for an adult. A mean and high intake estimate 
of about 450 mg/day and 790 mg/day, respectively, for adults are derived from an intake assessment 
based on conservative assumptions. Considering the nature, the natural occurrence and previous 
consumption of RCE constituents, the Panel is of the opinion that the margin between the intended as 
well as the estimated high percentile intake of RCE in relation to the highest dose administered to rats 
without adverse effects in a subchronic oral toxicity study is sufficient.  
CONCLUSION 
The Panel concludes that the novel food ingredient, Rooster Comb Extract, is safe under the proposed 
uses and use levels. 
DOCUMENTATION PROVIDED TO EFSA  
1. Dossier on „rooster comb extract‟. 9 June 2012. Submitted by Bioiberica A.S. Additional 
information was submitted on 9 January 2012 and on 21 February 2013. 
2. Letter from the European Commission to the European Food Safety Authority with the request 
for an opinion on the safety of „rooster comb extract‟. SANCO E6/AK/bs, Ref. Ares 
(2012)610804 – 22/05/2012. 
3. Initial assessment report carried out by the United Kingdom, „rooster comb extract‟ as novel food 
ingredients, Initial assessment under Article 4 of Regulation (EC) No 258/97”.  
4. Member States‟ comments and objections. 
5. Response by the applicant to the initial assessment report and the Member States' comments and 
objections. 
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ABBREVIATIONS 
Bw Bodyweight 
NF(I) Novel Food (Ingredient) 
NOAEL  No observed-adverse-effect level  
RCE Rooster comb extract 
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APPENDIX 1 
Table 5:  Mean intake estimate based on the sum of the estimated mean intake from the four food categories 2 
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 Age Group 
Total No of  
Subjects 
 % 
Consumers 
Mean  
(g) 
Mean 
(g) 
Mean 
(g) 
Mean 
(g) 
Mean 
(g) 
Mean 
(g) 
Mean 
(g) 
Mean  
(g) 
Mean 
(g) 
Mean 
(g) 
BELGIUM 
11-18 411 70.4 0.082 0.058 0.104 0.006 0.062 0.014 0.046 0.034 0.294 0.112 
19-64 820 62.9 0.049 0.03 0.191 0.004 0.069 0.025 0.058 0.046 0.367 0.105 
>65 303 58.5 0.034 0.02 0.115 0.001 0.083 0.028 0.054 0.043 0.286 0.092 
CYPRUS 19-64 264 87.1 0.085 0.074 0.121 0.002 0.019 0.007 0.039 0.032 0.264 0.115 
CZECH REP. 
11-18 288 96.6 0.072 0.07 0.095 0.003 0.081 0.038 0.039 0.030 0.287 0.141 
19-64 1484 89.1 0.041 0.036 0.124 - 0.081 0.027 0.048 0.033 0.294 0.096 
DENMARK 
11-18 478 99.8 0.136 0.136 0.102 0.057 0.046 0.034 0.029 0.028 0.313 0.255 
19-64 2816 99.8 0.102 0.101 0.073 0.023 0.045 0.03 0.033 0.033 0.253 0.187 
>65 309 100 0.092 0.092 0.062 0.011 0.06 0.037 0.029 0.028 0.243 0.168 
FINLAND 
19-64 1432 90.9 0.125 0.114 -* -* 0.127 0.073 0.048 0.039 0.300 0.226 
>65 432 93.3 0.124 0.116 -* -* 0.139 0.073 0.034 0.025 0.297 0.214 
FRANCE 
11-18 844 86.7 0.074 0.064 0.08 0.003 0.047 0.035 0.038 0.037 0.239 0.139 
19-64 1599 70.3 0.047 0.034 0.051 0.001 0.059 0.041 0.052 0.050 0.209 0.126 
>65 167 63.3 0.042 0.026 - - 0.054 0.033 0.057 0.056 0.153 0.115 
GERMANY 11-18 602 59.6 0.084 0.049 0.154 0.005 0.065 0.017 0.040 0.030 0.343 0.101 
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19-64 6011 57.7 0.062 0.035 0.155 0.002 0.081 0.029 0.049 0.039 0.347 0.105 
>65 989 49.3 0.054 0.026 0.128 - 0.080 0.033 0.047 0.04 0.309 0.099 
HUNGARY 
19-64 956 89.0 0.063 0.056 0.131 0.034 0.063 0.021 0.035 0.026 0.292 0.137 
>65 192 93.2 0.063 0.059 0.14 0.042 0.062 0.022 0.036 0.026 0.301 0.149 
IRELAND 19-64 949 99.1 0.107 0.106 0.229 - 0.029 0.01 0.021 0.018 0.386 0.134 
ITALY 
11-18 210 85.0 0.071 0.06 -* -* 0.052 0.011 0.065 0.063 0.188 0.134 
19-64 1742 75.3 0.054 0.041 -* -* 0.056 0.014 0.066 0.064 0.176 0.119 
>65 224 77.2 0.057 0.044 -* -* 0.052 0.01 0.058 0.056 0.167 0.110 
LATVIA 
11-18 231 49.2 0.055 0.027 0.118 0.001 0.082 0.033 0.036 0.022 0.291 0.083 
19-64 483 37.0 0.045 0.017 0.138 - 0.096 0.032 0.051 0.030 0.330 0.079 
THE 
NETHERLAND 
19-64 481 64.1 0.111 0.071 0.159 0.023 0.136 0.067 0.049 0.040 0.455 0.201 
SPAIN 
11-18 612 94.0 0.132 0.124 0.128 0.018 0.091 0.066 0.029 0.017 0.380 0.225 
19-64 939 95.7 0.123 0.117 0.072 0.002 0.061 0.036 0.031 0.023 0.287 0.178 
SWEDEN 
11 -18 952 93.5 0.133 0.124 0.11 0.04 0.08 0.041 0.019 0.012 0.342 0.217 
19-64 1041 86.0 0.109 0.094 0.043 - 0.094 0.058 0.033 0.031 0.279 0.183 
UNITED 
KINGDOM 
19-64 1673 97.0 0.086 0.084 0.034 0.003 0.033 0.014 0.025 0.022 0.178 0.123 
* The applicant did not provide figures for the respective food categories for Italy and Finland. On request to EFSA, the applicant responded that the food categories available in the database did not 3 
match with the food products intended by the applicant. The figures for the intake estimate fro all food categories are therefore an underestimate for the two countries.4 
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 5 
Table 6:  High intake scenario (sum of estimated mean intake from three food categories plus the highest 95th percentile intake which was estimated for “milk based 6 
 products”) 7 
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Total No 
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(g) 
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Mean 
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BELGIUM 11-18 411 70.4 0.082 0.058 0.062 0.014 0.046 0.034 0.219 0.052 0.19 0.106 0.409 0.158 
 
19-64 820 62.9 0.049 0.03 0.069 0.025 0.058 0.046 0.612 - 0.176 0.101 0.788 0.101 
>65 303 58.5 0.034 0.02 0.083 0.028 0.054 0.043 0.206 - 0.171 0.091 0.377  0.091 
CYPRUS 19-64 264 87.1 0.085 0.074 0.019 0.007 0.039 0.032 0.299 - 0.143 0.113 0.442 0.113 
CZECH REP. 11-18 288 96.6 0.072 0.07 0.081 0.038 0.039 0.03 0.12 - 0.192 0.138 0.312 0.138 
 19-64 1484 89.1 0.041 0.036 0.081 0.027 0.048 0.033 0.2 - 0.17 0.096 0.370 0.096 
DENMARK 11-18 478 99.8 0.136 0.136 0.046 0.034 0.029 0.028 0.297 0.229 0.211 0.198 0.508 0.427 
 
19-64 2816 99.8 0.102 0.101 0.045 0.03 0.033 0.033 0.229 0.114 0.18 0.164 0.409 0.278 
>65 309 100 0.092 0.092 0.06 0.037 0.029 0.028 0.183 0.069 0.181 0.157 0.364   0.226 
FINLAND 19-64 1432 90.9 0.125 0.114 0.127 0.073 0.048 0.039 -* -* 0.3 0.226 0.300 0.226 
 >65 432 93.3 0.124 0.116 0.139 0.073 0.034 0.025 -* -* 0.297 0.214 0.297 0.214 
FRANCE 11-18 844 86.7 0.074 0.064 0.047 0.035 0.038 0.037 0.229 - 0.159 0.136 0.388 0.136 
 19-64 1599 70.3 0.047 0.034 0.059 0.041 0.052 0.05 0.143 - 0.158 0.125 0.301 0.125 
Safety of „Rooster Combs Extract‟ 
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>65 167 63.26 0.042 0.026 0.054 0.033 0.057 0.056 - - 0.153 0.115 0.153 0.115 
GERMANY 11 18 602 59.6 0.084 0.049 0.065 0.017 0.04 0.03 0.247 - 0.189 0.096 0.436 0.096 
 
19-64 6011 57.7 0.062 0.035 0.081 0.029 0.049 0.039 0.4 - 0.192 0.103 0.592 0.103 
>65 989 49.3 0.054 0.026 0.08 0.033 0.047 0.04 0.178 - 0.181 0.099 0.359 0.099 
HUNGARY 19-64 956 89.0 0.063 0.056 0.063 0.021 0.035 0.026 0.373 0.160 0.161 0.103 0.534 0.263 
 >65 192 93.2 0.063 0.059 0.062 0.022 0.036 0.026 0.267 0.240 0.161 0.107 0.428 0.347 
IRELAND 19-64 949 99.1 0.107 0.106 0.029 0.01 0.021 0.018 0.229 - 0.157 0.134 0.386 0.134 
ITALY 11-18 210 85.0 0.071 0.06 0.052 0.011 0.065 0.063 -* -* 0.188 0.134 0.188 0.134 
 
19-64 1742 75.3 0.054 0.041 0.056 0.014 0.066 0.064 -* -* 0.176 0.119 0.176 0.119 
>65 224 77.2 0.057 0.044 0.052 0.01 0.058 0.056 -* -* 0.167 0.11 0.167 0.110 
LATVIA 11-18 231 49.2 0.055 0.027 0.082 0.033 0.036 0.022 0.2 - 0.173 0.082 0.373 0.082 
 19-64 483 37.0 0.045 0.017 0.096 0.032 0.051 0.03 0.176 - 0.192 0.079 0.368 0.079 
THE 
NETHERLANDS 
19-64 481 64.1 0.111 0.071 0.136 0.067 0.049 0.04 0.4 0.160 0.296 0.178 0.696 0.338 
SPAIN 11-18 612 94.0 0.132 0.124 0.091 0.066 0.029 0.017 0.264 0.132 0.252 0.207 0.516 0.339 
 19-64 939 95.7 0.123 0.117 0.061 0.036 0.031 0.023 0.187 - 0.215 0.176 0.402 0.176 
SWEDEN 11-18 952 93.5 0.133 0.124 0.08 0.041 0.019 0.012 0.286 0.190 0.232 0.177 0.518 0.367 
 19-64 1041 86.0 0.109 0.094 0.094 0.058 0.033 0.031 0.107 - 0.236 0.183 0.343 0.183 
UNITED 
KINGDOM 
19-64 1673 97.0 0.086 0.084 0.033 0.014 0.025 0.022 0.111 0.012 0.144 0.12 0.255 0.132 
* The applicant did not provide figures for the respective food categories for Italy and Finland. On request to EFSA, the applicant responded that the food categories available in the database did not 8 
match with the food products intended by the applicant. The figures for the intake estimate fro all food categories are therefore an underestimate for the two countries. 9 
